234 related articles for article (PubMed ID: 34634968)
1. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
3. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
[TBL] [Abstract][Full Text] [Related]
6. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
7. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
8. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
[TBL] [Abstract][Full Text] [Related]
9. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
10. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
[TBL] [Abstract][Full Text] [Related]
12. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
Signori A; Ponzano M; Alexandri N; Giovannoni G; Sormani MP
Eur J Neurol; 2022 Jul; 29(7):2144-2147. PubMed ID: 35258154
[TBL] [Abstract][Full Text] [Related]
14. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
[TBL] [Abstract][Full Text] [Related]
15. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
[TBL] [Abstract][Full Text] [Related]
16. Cladribine Tablets: A Review in Relapsing MS.
Deeks ED
CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
[TBL] [Abstract][Full Text] [Related]
17. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
18. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
20. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]